Header Logo

Connection

HELEN HESLOP to Humans

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about Humans.
HELEN HESLOP
Connection Strength
1.643
Humans
  1. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.
    View in: PubMed
    Score: 0.024
  2. Time to optimize vaccination strategies in blood cancer patients. Br J Haematol. 2024 Aug; 205(2):406-408.
    View in: PubMed
    Score: 0.023
  3. Data mining for second malignancies after CAR-T. Blood. 2024 05 16; 143(20):2023-2024.
    View in: PubMed
    Score: 0.023
  4. A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help. Blood Adv. 2024 02 27; 8(4):1053-1061.
    View in: PubMed
    Score: 0.022
  5. Introduction to a How I Treat series on emergent CAR T-cell toxicities. Blood. 2023 05 18; 141(20):2405-2407.
    View in: PubMed
    Score: 0.021
  6. Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant? Best Pract Res Clin Haematol. 2022 12; 35(4):101414.
    View in: PubMed
    Score: 0.020
  7. Tumor-intrinsic causes of CAR-T failure. Blood. 2022 08 04; 140(5):414-415.
    View in: PubMed
    Score: 0.020
  8. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.020
  9. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 11; 27(11):885-907.
    View in: PubMed
    Score: 0.019
  10. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
    View in: PubMed
    Score: 0.018
  11. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021 02 10; 39(5):514-524.
    View in: PubMed
    Score: 0.018
  12. Sensitizing Burkitt lymphoma to EBV-CTLs. Blood. 2020 05 21; 135(21):1822-1823.
    View in: PubMed
    Score: 0.017
  13. Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. Mol Ther. 2019 05 08; 27(5):900-901.
    View in: PubMed
    Score: 0.016
  14. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. Cancer Immunol Res. 2019 04; 7(4):528-533.
    View in: PubMed
    Score: 0.016
  15. Harmonizing Immune Effector Toxicity Reporting. Biol Blood Marrow Transplant. 2019 04; 25(4):e121-e122.
    View in: PubMed
    Score: 0.016
  16. A backpack revs up T-cell activity. Nat Biotechnol. 2018 08 06; 36(8):702-703.
    View in: PubMed
    Score: 0.015
  17. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386.
    View in: PubMed
    Score: 0.015
  18. Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2.
    View in: PubMed
    Score: 0.015
  19. Equal opportunity CAR T cells. Blood. 2017 06 22; 129(25):3275-3277.
    View in: PubMed
    Score: 0.014
  20. Exhausting alloreactivity of donor-derived CAR T cells. Nat Med. 2017 02 07; 23(2):147-148.
    View in: PubMed
    Score: 0.014
  21. Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540.
    View in: PubMed
    Score: 0.014
  22. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396.
    View in: PubMed
    Score: 0.014
  23. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704.
    View in: PubMed
    Score: 0.014
  24. Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov. 2016 06; 6(6):579-80.
    View in: PubMed
    Score: 0.013
  25. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016 06 30; 127(26):3331-40.
    View in: PubMed
    Score: 0.013
  26. Engineering haploidentical transplants. Bone Marrow Transplant. 2015 Jul; 50(7):884-5.
    View in: PubMed
    Score: 0.012
  27. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014 Nov; 21(6):476-81.
    View in: PubMed
    Score: 0.012
  28. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.
    View in: PubMed
    Score: 0.011
  29. T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55.
    View in: PubMed
    Score: 0.011
  30. Combining drugs and biologics to treat nasopharyngeal cancer. Mol Ther. 2014 Jan; 22(1):8-9.
    View in: PubMed
    Score: 0.011
  31. Genetic engineering of T-cell receptors: TCR takes to titin. Blood. 2013 Aug 08; 122(6):853-4.
    View in: PubMed
    Score: 0.011
  32. Pharmacotherapy versus T lymphocytes for CMV. Blood. 2013 May 02; 121(18):3544-5.
    View in: PubMed
    Score: 0.011
  33. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.011
  34. T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program. 2013; 2013:342-7.
    View in: PubMed
    Score: 0.010
  35. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9.
    View in: PubMed
    Score: 0.010
  36. Getting personal with melanoma. Clin Cancer Res. 2011 Jul 01; 17(13):4189-91.
    View in: PubMed
    Score: 0.009
  37. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun; 16(3):274-80.
    View in: PubMed
    Score: 0.009
  38. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9.
    View in: PubMed
    Score: 0.009
  39. CARs on track in the clinic. Mol Ther. 2011 Mar; 19(3):432-8.
    View in: PubMed
    Score: 0.009
  40. Safer CARS. Mol Ther. 2010 Apr; 18(4):661-2.
    View in: PubMed
    Score: 0.009
  41. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
    View in: PubMed
    Score: 0.008
  42. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
    View in: PubMed
    Score: 0.008
  43. How I treat EBV lymphoproliferation. Blood. 2009 Nov 05; 114(19):4002-8.
    View in: PubMed
    Score: 0.008
  44. The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
    View in: PubMed
    Score: 0.008
  45. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008 Sep; 21(3):405-20.
    View in: PubMed
    Score: 0.008
  46. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008 Oct; 143(2):169-79.
    View in: PubMed
    Score: 0.008
  47. Pediatric blood and marrow transplantation: state of the science. Bone Marrow Transplant. 2008 Jan; 41(2):97.
    View in: PubMed
    Score: 0.007
  48. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008 Jan; 41(2):193-8.
    View in: PubMed
    Score: 0.007
  49. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.007
  50. Gene therapy. Cytotherapy. 2007; 9(6):519-20.
    View in: PubMed
    Score: 0.007
  51. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9.
    View in: PubMed
    Score: 0.007
  52. Viral lymphomagenesis. Curr Opin Hematol. 2006 Jul; 13(4):254-9.
    View in: PubMed
    Score: 0.007
  53. Commentary on journal of immunotherapy paper by melenhorst et al. J Immunother. 2006 Jul-Aug; 29(4):365-6.
    View in: PubMed
    Score: 0.007
  54. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol. 2006 Jun; 84(3):281-9.
    View in: PubMed
    Score: 0.007
  55. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42.
    View in: PubMed
    Score: 0.007
  56. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nat Med. 2026 01; 32(1):258-269.
    View in: PubMed
    Score: 0.006
  57. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7.
    View in: PubMed
    Score: 0.006
  58. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
    View in: PubMed
    Score: 0.006
  59. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44.
    View in: PubMed
    Score: 0.006
  60. Current status of genetic modification of T cells for cancer treatment. Cytotherapy. 2005; 7(3):262-72.
    View in: PubMed
    Score: 0.006
  61. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 260-6.
    View in: PubMed
    Score: 0.006
  62. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33.
    View in: PubMed
    Score: 0.006
  63. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 01; 637(8047):940-946.
    View in: PubMed
    Score: 0.006
  64. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904.
    View in: PubMed
    Score: 0.006
  65. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.006
  66. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13.
    View in: PubMed
    Score: 0.006
  67. Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
    View in: PubMed
    Score: 0.006
  68. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 08 07; 32(8):2444-2460.
    View in: PubMed
    Score: 0.006
  69. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 08 10; 42(23):2769-2779.
    View in: PubMed
    Score: 0.006
  70. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.006
  71. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
    View in: PubMed
    Score: 0.006
  72. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.006
  73. Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
    View in: PubMed
    Score: 0.006
  74. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55.
    View in: PubMed
    Score: 0.006
  75. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 02; 30(2):338-341.
    View in: PubMed
    Score: 0.006
  76. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
    View in: PubMed
    Score: 0.006
  77. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy. Cytotherapy. 2024 03; 26(3):261-265.
    View in: PubMed
    Score: 0.006
  78. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 02; 30(2):217-227.
    View in: PubMed
    Score: 0.005
  79. Moving CAR-Ts to the outpatient clinic. Br J Haematol. 2023 11; 203(4):507-508.
    View in: PubMed
    Score: 0.005
  80. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
    View in: PubMed
    Score: 0.005
  81. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.005
  82. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
    View in: PubMed
    Score: 0.005
  83. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
    View in: PubMed
    Score: 0.005
  84. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev. 2003 Feb; 29(1):3-10.
    View in: PubMed
    Score: 0.005
  85. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther. 2023 04; 29(4):228-239.
    View in: PubMed
    Score: 0.005
  86. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
    View in: PubMed
    Score: 0.005
  87. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98.
    View in: PubMed
    Score: 0.005
  88. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.005
  89. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48.
    View in: PubMed
    Score: 0.005
  90. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53.
    View in: PubMed
    Score: 0.005
  91. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003; 331-49.
    View in: PubMed
    Score: 0.005
  92. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
    View in: PubMed
    Score: 0.005
  93. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
    View in: PubMed
    Score: 0.005
  94. Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther. 2002 Oct; 4(5):467-75.
    View in: PubMed
    Score: 0.005
  95. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
    View in: PubMed
    Score: 0.005
  96. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.005
  97. [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]. Arch Pediatr. 2002 Mar; 9(3):289-306.
    View in: PubMed
    Score: 0.005
  98. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
    View in: PubMed
    Score: 0.005
  99. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022 01 25; 6(2):452-459.
    View in: PubMed
    Score: 0.005
  100. Immunotherapy to reconstitute immunity to DNA viruses. Semin Hematol. 2002 Jan; 39(1):41-7.
    View in: PubMed
    Score: 0.005
  101. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(1):1-8.
    View in: PubMed
    Score: 0.005
  102. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
    View in: PubMed
    Score: 0.005
  103. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
    View in: PubMed
    Score: 0.005
  104. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
    View in: PubMed
    Score: 0.005
  105. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633.
    View in: PubMed
    Score: 0.005
  106. Beyond CD19 CAR-T cells in lymphoma. Curr Opin Immunol. 2022 02; 74:46-52.
    View in: PubMed
    Score: 0.005
  107. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 01; 98(7):2052-8.
    View in: PubMed
    Score: 0.005
  108. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422.
    View in: PubMed
    Score: 0.005
  109. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.005
  110. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539.
    View in: PubMed
    Score: 0.005
  111. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
    View in: PubMed
    Score: 0.005
  112. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. Bone Marrow Transplant. 2021 11; 56(11):2797-2803.
    View in: PubMed
    Score: 0.005
  113. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation. J Immunother. 2001 Jul-Aug; 24(4):283-4.
    View in: PubMed
    Score: 0.005
  114. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther. 2001 Jul; 1(4):663-74.
    View in: PubMed
    Score: 0.005
  115. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6.
    View in: PubMed
    Score: 0.005
  116. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.005
  117. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.005
  118. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9.
    View in: PubMed
    Score: 0.004
  119. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
    View in: PubMed
    Score: 0.004
  120. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
    View in: PubMed
    Score: 0.004
  121. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
    View in: PubMed
    Score: 0.004
  122. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
    View in: PubMed
    Score: 0.004
  123. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
    View in: PubMed
    Score: 0.004
  124. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
    View in: PubMed
    Score: 0.004
  125. CRISPR-Edited Immune Effectors: The End of the Beginning. Mol Ther. 2020 04 08; 28(4):995-996.
    View in: PubMed
    Score: 0.004
  126. Gene therapy of pediatric leukemia. Clin Lab Med. 2000 Mar; 20(1):183-95, x.
    View in: PubMed
    Score: 0.004
  127. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
    View in: PubMed
    Score: 0.004
  128. Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2020 05; 26(5):e94-e100.
    View in: PubMed
    Score: 0.004
  129. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
    View in: PubMed
    Score: 0.004
  130. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.004
  131. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
    View in: PubMed
    Score: 0.004
  132. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580.
    View in: PubMed
    Score: 0.004
  133. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
    View in: PubMed
    Score: 0.004
  134. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 10; 187(2):206-218.
    View in: PubMed
    Score: 0.004
  135. Haemopoietic stem cell transplantation from unrelated donors. Br J Haematol. 1999 Apr; 105(1):2-6.
    View in: PubMed
    Score: 0.004
  136. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101.
    View in: PubMed
    Score: 0.004
  137. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999; 14(3):154-6.
    View in: PubMed
    Score: 0.004
  138. Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. Cytotherapy. 1999; 1(6):433-8.
    View in: PubMed
    Score: 0.004
  139. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 03; 25(3):e76-e85.
    View in: PubMed
    Score: 0.004
  140. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.004
  141. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.004
  142. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
    View in: PubMed
    Score: 0.004
  143. Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy. 2018 09; 20(9):1182-1190.
    View in: PubMed
    Score: 0.004
  144. Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24.
    View in: PubMed
    Score: 0.004
  145. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.004
  146. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
    View in: PubMed
    Score: 0.004
  147. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
    View in: PubMed
    Score: 0.004
  148. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.004
  149. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93.
    View in: PubMed
    Score: 0.004
  150. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
    View in: PubMed
    Score: 0.004
  151. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.004
  152. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997 Sep 13; 350(9080):767-71.
    View in: PubMed
    Score: 0.004
  153. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
    View in: PubMed
    Score: 0.004
  154. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.004
  155. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.004
  156. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
    View in: PubMed
    Score: 0.004
  157. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997 Jun; 157:217-22.
    View in: PubMed
    Score: 0.004
  158. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.003
  159. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30.
    View in: PubMed
    Score: 0.003
  160. Measuring gene-transfer efficiency. Nat Med. 1996 Dec; 2(12):1280-1.
    View in: PubMed
    Score: 0.003
  161. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.003
  162. Policy: Global standards for stem-cell research. Nature. 2016 05 19; 533(7603):311-3.
    View in: PubMed
    Score: 0.003
  163. New ISSCR guidelines: clinical translation of stem cell research. Lancet. 2016 May 14; 387(10032):1979-81.
    View in: PubMed
    Score: 0.003
  164. Setting Global Standards for Stem Cell Research and Clinical Translation: The?2016 ISSCR Guidelines. Stem Cell Reports. 2016 06 14; 6(6):787-797.
    View in: PubMed
    Score: 0.003
  165. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5.
    View in: PubMed
    Score: 0.003
  166. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
    View in: PubMed
    Score: 0.003
  167. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
    View in: PubMed
    Score: 0.003
  168. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
    View in: PubMed
    Score: 0.003
  169. Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
    View in: PubMed
    Score: 0.003
  170. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31.
    View in: PubMed
    Score: 0.003
  171. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
    View in: PubMed
    Score: 0.003
  172. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
    View in: PubMed
    Score: 0.003
  173. Gene transfer for the therapy of hematologic malignancy. Curr Opin Hematol. 1995 Nov; 2(6):417-22.
    View in: PubMed
    Score: 0.003
  174. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
    View in: PubMed
    Score: 0.003
  175. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
    View in: PubMed
    Score: 0.003
  176. Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73.
    View in: PubMed
    Score: 0.003
  177. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.003
  178. Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). J Clin Immunol. 2015 Jul; 35(5):445-8.
    View in: PubMed
    Score: 0.003
  179. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
    View in: PubMed
    Score: 0.003
  180. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63.
    View in: PubMed
    Score: 0.003
  181. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.003
  182. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
    View in: PubMed
    Score: 0.003
  183. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
    View in: PubMed
    Score: 0.003
  184. Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
    View in: PubMed
    Score: 0.003
  185. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
    View in: PubMed
    Score: 0.003
  186. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest. 2015 Jan; 125(1):157-68.
    View in: PubMed
    Score: 0.003
  187. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24.
    View in: PubMed
    Score: 0.003
  188. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83.
    View in: PubMed
    Score: 0.003
  189. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80.
    View in: PubMed
    Score: 0.003
  190. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74.
    View in: PubMed
    Score: 0.003
  191. Reply to S. Yuan et al. J Clin Oncol. 2014 Sep 01; 32(25):2820-1.
    View in: PubMed
    Score: 0.003
  192. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.003
  193. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
    View in: PubMed
    Score: 0.003
  194. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
    View in: PubMed
    Score: 0.003
  195. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.003
  196. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 07; 49(7):986-7.
    View in: PubMed
    Score: 0.003
  197. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.003
  198. Immunotherapy: opportunities, risks and future perspectives. Cytotherapy. 2014 Apr; 16(4 Suppl):S120-9.
    View in: PubMed
    Score: 0.003
  199. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
    View in: PubMed
    Score: 0.003
  200. Epstein-Barr infection after bone marrow transplantation. Blood. 1994 Mar 15; 83(6):1706-8.
    View in: PubMed
    Score: 0.003
  201. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.003
  202. Cytokine gene transfer in the therapy of malignancy. Baillieres Clin Haematol. 1994 Mar; 7(1):135-51.
    View in: PubMed
    Score: 0.003
  203. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
    View in: PubMed
    Score: 0.003
  204. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
    View in: PubMed
    Score: 0.003
  205. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 Feb; 13(2):221-3.
    View in: PubMed
    Score: 0.003
  206. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.003
  207. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
    View in: PubMed
    Score: 0.003
  208. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.003
  209. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96.
    View in: PubMed
    Score: 0.003
  210. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.003
  211. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8.
    View in: PubMed
    Score: 0.003
  212. TNF and chronic B lymphoproliferative disorders. Leukemia. 1993 Sep; 7(9):1476.
    View in: PubMed
    Score: 0.003
  213. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
    View in: PubMed
    Score: 0.003
  214. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.003
  215. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62.
    View in: PubMed
    Score: 0.003
  216. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013 Feb 15; 95(3):519-26.
    View in: PubMed
    Score: 0.003
  217. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76.
    View in: PubMed
    Score: 0.003
  218. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
    View in: PubMed
    Score: 0.003
  219. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
    View in: PubMed
    Score: 0.003
  220. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17.
    View in: PubMed
    Score: 0.003
  221. New approaches in alternative donor transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S91-6.
    View in: PubMed
    Score: 0.003
  222. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32.
    View in: PubMed
    Score: 0.003
  223. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9.
    View in: PubMed
    Score: 0.002
  224. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.002
  225. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11.
    View in: PubMed
    Score: 0.002
  226. Immunotherapy of leukemia. Leukemia. 1992; 6 Suppl 1:76-9.
    View in: PubMed
    Score: 0.002
  227. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
    View in: PubMed
    Score: 0.002
  228. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
    View in: PubMed
    Score: 0.002
  229. Definitions of histocompatibility typing terms. Blood. 2011 Dec 01; 118(23):e180-3.
    View in: PubMed
    Score: 0.002
  230. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
    View in: PubMed
    Score: 0.002
  231. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
    View in: PubMed
    Score: 0.002
  232. Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
    View in: PubMed
    Score: 0.002
  233. Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br J Haematol. 1991 Oct; 79 Suppl 1:14-6.
    View in: PubMed
    Score: 0.002
  234. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
    View in: PubMed
    Score: 0.002
  235. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66.
    View in: PubMed
    Score: 0.002
  236. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39.
    View in: PubMed
    Score: 0.002
  237. Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49.
    View in: PubMed
    Score: 0.002
  238. Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. Hum Immunol. 2011 Dec; 72(12):1214-6.
    View in: PubMed
    Score: 0.002
  239. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267.
    View in: PubMed
    Score: 0.002
  240. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86.
    View in: PubMed
    Score: 0.002
  241. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
    View in: PubMed
    Score: 0.002
  242. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.002
  243. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr; 153(1):76-82.
    View in: PubMed
    Score: 0.002
  244. Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc. 1991 Feb; 23(1 Pt 2):1704-5.
    View in: PubMed
    Score: 0.002
  245. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol. 1991 Feb; 77(2):237-44.
    View in: PubMed
    Score: 0.002
  246. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62.
    View in: PubMed
    Score: 0.002
  247. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
    View in: PubMed
    Score: 0.002
  248. Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20.
    View in: PubMed
    Score: 0.002
  249. Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2011 Feb; 17(2):192-6.
    View in: PubMed
    Score: 0.002
  250. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 01; 172(6):1729-34.
    View in: PubMed
    Score: 0.002
  251. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
    View in: PubMed
    Score: 0.002
  252. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
    View in: PubMed
    Score: 0.002
  253. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
    View in: PubMed
    Score: 0.002
  254. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80.
    View in: PubMed
    Score: 0.002
  255. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
    View in: PubMed
    Score: 0.002
  256. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
    View in: PubMed
    Score: 0.002
  257. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010 Apr; 33(3):305-15.
    View in: PubMed
    Score: 0.002
  258. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81.
    View in: PubMed
    Score: 0.002
  259. Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. Biol Blood Marrow Transplant. 2010 May; 16(5):595-7.
    View in: PubMed
    Score: 0.002
  260. T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am. 2010 Feb; 57(1):83-96.
    View in: PubMed
    Score: 0.002
  261. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
    View in: PubMed
    Score: 0.002
  262. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72.
    View in: PubMed
    Score: 0.002
  263. Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. Acad Radiol. 2010 Apr; 17(4):479-88.
    View in: PubMed
    Score: 0.002
  264. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15; 16(2):474-85.
    View in: PubMed
    Score: 0.002
  265. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009 Nov 18; 8:106.
    View in: PubMed
    Score: 0.002
  266. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1493-501.
    View in: PubMed
    Score: 0.002
  267. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
    View in: PubMed
    Score: 0.002
  268. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep; 74(4):1374-80.
    View in: PubMed
    Score: 0.002
  269. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
    View in: PubMed
    Score: 0.002
  270. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
    View in: PubMed
    Score: 0.002
  271. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.002
  272. Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol. 1989 Jun; 72(2):122-6.
    View in: PubMed
    Score: 0.002
  273. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
    View in: PubMed
    Score: 0.002
  274. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
    View in: PubMed
    Score: 0.002
  275. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
    View in: PubMed
    Score: 0.002
  276. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
    View in: PubMed
    Score: 0.002
  277. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
    View in: PubMed
    Score: 0.002
  278. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
    View in: PubMed
    Score: 0.002
  279. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
    View in: PubMed
    Score: 0.002
  280. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34.
    View in: PubMed
    Score: 0.002
  281. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
    View in: PubMed
    Score: 0.002
  282. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85.
    View in: PubMed
    Score: 0.002
  283. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
    View in: PubMed
    Score: 0.002
  284. In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J Immunol. 1988 May 15; 140(10):3461-6.
    View in: PubMed
    Score: 0.002
  285. T cell therapy in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):136-41.
    View in: PubMed
    Score: 0.002
  286. Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy. 2008; 10(5):526-39.
    View in: PubMed
    Score: 0.002
  287. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1268-85.
    View in: PubMed
    Score: 0.002
  288. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54.
    View in: PubMed
    Score: 0.002
  289. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
    View in: PubMed
    Score: 0.002
  290. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
    View in: PubMed
    Score: 0.002
  291. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5.
    View in: PubMed
    Score: 0.002
  292. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.002
  293. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
    View in: PubMed
    Score: 0.002
  294. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
    View in: PubMed
    Score: 0.002
  295. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86.
    View in: PubMed
    Score: 0.002
  296. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.002
  297. Sustained complete remission in Richter's syndrome. Cancer. 1987 Mar 01; 59(5):1036-9.
    View in: PubMed
    Score: 0.002
  298. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
    View in: PubMed
    Score: 0.002
  299. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007 Mar 15; 109(6):2657-62.
    View in: PubMed
    Score: 0.002
  300. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94.
    View in: PubMed
    Score: 0.002
  301. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.002
  302. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
    View in: PubMed
    Score: 0.002
  303. Twin pregnancy and parturition in a patient with the Bernard Soulier syndrome. Scand J Haematol. 1986 Jul; 37(1):71-3.
    View in: PubMed
    Score: 0.002
  304. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
    View in: PubMed
    Score: 0.002
  305. Allogeneic bone marrow transplantation at Christchurch 1979-1985. N Z Med J. 1986 May 14; 99(801):318-21.
    View in: PubMed
    Score: 0.002
  306. ASBMT committee report: white paper on measurement of quality outcomes. Biol Blood Marrow Transplant. 2006 May; 12(5):594-7.
    View in: PubMed
    Score: 0.002
  307. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
    View in: PubMed
    Score: 0.002
  308. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93.
    View in: PubMed
    Score: 0.002
  309. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52.
    View in: PubMed
    Score: 0.002
  310. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
    View in: PubMed
    Score: 0.002
  311. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005 Dec; 36(11):1001-8.
    View in: PubMed
    Score: 0.002
  312. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.
    View in: PubMed
    Score: 0.002
  313. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802.
    View in: PubMed
    Score: 0.002
  314. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant. 2005 Nov; 11(11):912-20.
    View in: PubMed
    Score: 0.002
  315. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41.
    View in: PubMed
    Score: 0.002
  316. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47.
    View in: PubMed
    Score: 0.002
  317. Hyponatraemic-hypertensive syndrome due to unilateral renal ischaemia in women who smoke heavily. N Z Med J. 1985 Sep 11; 98(786):739-42.
    View in: PubMed
    Score: 0.002
  318. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8.
    View in: PubMed
    Score: 0.002
  319. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41.
    View in: PubMed
    Score: 0.002
  320. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
    View in: PubMed
    Score: 0.002
  321. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005 Mar; 5(3):566-72.
    View in: PubMed
    Score: 0.002
  322. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
    View in: PubMed
    Score: 0.001
  323. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10.
    View in: PubMed
    Score: 0.001
  324. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
    View in: PubMed
    Score: 0.001
  325. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7.
    View in: PubMed
    Score: 0.001
  326. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
    View in: PubMed
    Score: 0.001
  327. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
    View in: PubMed
    Score: 0.001
  328. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70.
    View in: PubMed
    Score: 0.001
  329. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91.
    View in: PubMed
    Score: 0.001
  330. Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. Am J Hematol. 2004 Jan; 75(1):48-51.
    View in: PubMed
    Score: 0.001
  331. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant. 2003 Nov; 9(11):698-705.
    View in: PubMed
    Score: 0.001
  332. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant. 2003 Jun; 31(11):981-6.
    View in: PubMed
    Score: 0.001
  333. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
    View in: PubMed
    Score: 0.001
  334. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
    View in: PubMed
    Score: 0.001
  335. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56.
    View in: PubMed
    Score: 0.001
  336. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
    View in: PubMed
    Score: 0.001
  337. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40.
    View in: PubMed
    Score: 0.001
  338. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9.
    View in: PubMed
    Score: 0.001
  339. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003 Mar 01; 101(5):1905-12.
    View in: PubMed
    Score: 0.001
  340. Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 Oct 15; 74(7):1050-2.
    View in: PubMed
    Score: 0.001
  341. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002 Sep; 118(3):728-40.
    View in: PubMed
    Score: 0.001
  342. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
    View in: PubMed
    Score: 0.001
  343. Energy expenditure in children undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Jul; 30(2):125-30.
    View in: PubMed
    Score: 0.001
  344. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87.
    View in: PubMed
    Score: 0.001
  345. Guillain-Barr? syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(6):515-7.
    View in: PubMed
    Score: 0.001
  346. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18.
    View in: PubMed
    Score: 0.001
  347. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33.
    View in: PubMed
    Score: 0.001
  348. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002; 84:175-201.
    View in: PubMed
    Score: 0.001
  349. Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy. 2002; 4(3):253-8.
    View in: PubMed
    Score: 0.001
  350. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001 Sep 27; 72(6):1078-86.
    View in: PubMed
    Score: 0.001
  351. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
    View in: PubMed
    Score: 0.001
  352. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
    View in: PubMed
    Score: 0.001
  353. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
    View in: PubMed
    Score: 0.001
  354. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant. 2001 Jan; 27(2):155-62.
    View in: PubMed
    Score: 0.001
  355. Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
    View in: PubMed
    Score: 0.001
  356. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma. 2000 Nov; 39(5-6):455-64.
    View in: PubMed
    Score: 0.001
  357. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
    View in: PubMed
    Score: 0.001
  358. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999 Oct; 24(7):735-9.
    View in: PubMed
    Score: 0.001
  359. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 Feb; 23(3):277-82.
    View in: PubMed
    Score: 0.001
  360. Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. Pediatr Radiol. 1998 Jul; 28(7):492-6.
    View in: PubMed
    Score: 0.001
  361. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
    View in: PubMed
    Score: 0.001
  362. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15; 91(8):2925-34.
    View in: PubMed
    Score: 0.001
  363. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
    View in: PubMed
    Score: 0.001
  364. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
    View in: PubMed
    Score: 0.001
  365. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38.
    View in: PubMed
    Score: 0.001
  366. Hepatic arterial resistance index--an indicator of diffuse liver disease in children treated with bone marrow transplantation. Clin Radiol. 1997 Dec; 52(12):903-6.
    View in: PubMed
    Score: 0.001
  367. A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus. Genomics. 1997 Jan 01; 39(1):55-65.
    View in: PubMed
    Score: 0.001
  368. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
    View in: PubMed
    Score: 0.001
  369. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996 Oct; 23(3-4):213-20.
    View in: PubMed
    Score: 0.001
  370. Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
    View in: PubMed
    Score: 0.001
  371. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47.
    View in: PubMed
    Score: 0.001
  372. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995 Dec; 9(12):1990-6.
    View in: PubMed
    Score: 0.001
  373. Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade. J Ultrasound Med. 1995 Nov; 14(11):877-9.
    View in: PubMed
    Score: 0.001
  374. T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient. Cancer Immunol Immunother. 1995 Aug; 41(2):104-10.
    View in: PubMed
    Score: 0.001
  375. Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35.
    View in: PubMed
    Score: 0.001
  376. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
    View in: PubMed
    Score: 0.001
  377. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3.
    View in: PubMed
    Score: 0.001
  378. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 1994 May 31; 716:204-14; discussion 214-5, 225-7.
    View in: PubMed
    Score: 0.001
  379. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
    View in: PubMed
    Score: 0.001
  380. Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
    View in: PubMed
    Score: 0.001
  381. Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6.
    View in: PubMed
    Score: 0.001
  382. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
    View in: PubMed
    Score: 0.001
  383. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan; 11(1):33-6.
    View in: PubMed
    Score: 0.001
  384. Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. Bone Marrow Transplant. 1992 Dec; 10(6):521-7.
    View in: PubMed
    Score: 0.001
  385. IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8.
    View in: PubMed
    Score: 0.001
  386. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood. 1991 May 01; 77(9):1996-2001.
    View in: PubMed
    Score: 0.001
  387. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991 Apr; 11(4):1912-20.
    View in: PubMed
    Score: 0.001
  388. Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. Blood. 1991 Mar 15; 77(6):1283-9.
    View in: PubMed
    Score: 0.001
  389. Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53.
    View in: PubMed
    Score: 0.001
  390. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990 Aug; 75(4):499-505.
    View in: PubMed
    Score: 0.001
  391. Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol. 1990 Jan 15; 144(2):541-7.
    View in: PubMed
    Score: 0.001
  392. The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage. Acta Haematol. 1990; 83(4):203-5.
    View in: PubMed
    Score: 0.001
  393. Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol. 1989 Dec 01; 143(11):3828-34.
    View in: PubMed
    Score: 0.001
  394. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989 Dec; 73(4):468-74.
    View in: PubMed
    Score: 0.001
  395. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42.
    View in: PubMed
    Score: 0.001
  396. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer. 1989 Oct; 60(4):610-5.
    View in: PubMed
    Score: 0.001
  397. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
    View in: PubMed
    Score: 0.000
  398. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30; 1(8592):969-71.
    View in: PubMed
    Score: 0.000
  399. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol (1978). 1988; 30(5-6):317-9.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.